Cosmos Health, Inc.

How big is Cosmos Health, Inc.?

As of Jun 18, Cosmos Health, Inc. has a market capitalization of 12.40 million, with net sales of 53.55 million and a net profit of -15.13 million over the latest four quarters. Shareholder's funds are reported at 24.53 million, and total assets amount to 54.31 million.

As of Jun 18, Cosmos Health, Inc. has a market capitalization of 12.40 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 53.55 million, while the sum of net profit for the same period is -15.13 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 24.53 million, and total assets amount to 54.31 million.

What does Cosmos Health, Inc. do?

Cosmos Health, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $14 million and a net profit of -$1 million. It has a market cap of $12.40 million and key metrics indicating a loss-making status.

Overview: <BR>Cosmos Health, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 14 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 12.40 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.45 <BR>Return on Equity: -57.21% <BR>Price to Book: 0.48<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Cosmos Health, Inc.?

Is Cosmos Health, Inc. overvalued or undervalued?

Cosmos Health, Inc. is considered overvalued and risky due to negative valuation ratios and poor long-term performance, despite a strong year-to-date return of 39.30% compared to the S&P 500's 12.22%.

As of 18 May 2016, the valuation grade for Cosmos Health, Inc. moved from does not qualify to risky, indicating a deterioration in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of 0.54, an EV to EBIT of -1.87, and an EV to EBITDA of -2.06. In comparison, TFF Pharmaceuticals, Inc. has a less negative EV to EBITDA of 0.1173, suggesting that Cosmos is struggling relative to its peers.<BR><BR>The company's recent stock performance shows a 39.30% return year-to-date, significantly outperforming the S&P 500's 12.22% return in the same period. However, over longer horizons, such as the 3-year and 5-year returns of -89.93% and -98.82%, respectively, indicate severe underperformance compared to the S&P 500's gains. Overall, Cosmos Health, Inc. is deemed overvalued based on its financial metrics and peer comparisons.

Is Cosmos Health, Inc. technically bullish or bearish?

As of September 11, 2025, Cosmos Health, Inc. shows a bullish technical trend with positive momentum from moving averages and MACD, despite a bearish weekly RSI and negative long-term performance compared to the S&P 500.

As of 11 September 2025, the technical trend for Cosmos Health, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are also bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly and bullish on the monthly, reinforcing the upward trend. The KST is bullish weekly and mildly bullish monthly, while the OBV is bullish monthly, indicating accumulation.<BR><BR>In terms of performance, Cosmos Health has outperformed the S&P 500 over the past week and month, with returns of 10.95% and 9.88% respectively, compared to 1.05% and 2.33% for the index. However, the longer-term returns (1Y, 3Y, 5Y, and 10Y) are significantly negative compared to the S&P 500, indicating a challenging historical performance.<BR><BR>Overall, the current technical stance is bullish, driven primarily by the positive signals from moving averages and MACD, despite some mixed signals from the RSI and longer-term performance.